1. Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. A, FGFR4 signaling was examined in Hep 3B tumors following twice-daily (bid) treatment with BLU9931 at indicated doses for a total of 4 doses. Hep 3B tumors were harvested at indicated times following the last dose. CYP7A1 mRNA levels were determined using qRT-PCR (3 mice/group) and are expressed relative to levels in tumors from vehicle-treated mice. The concentration of BLU9931 in plasma is expressed for each time point in ng/mL. B, In vivo antitumor efficacy of BLU9931 in Hep 3B tumors. BLU9931 was administered orally (po), twice daily at the indicated doses (9 mice/group). Sorafenib was administered orally once daily (qd) at 30 mg/kg (9 mice/group). Data are plotted as mean ± SEM. C, body weight was monitored during treatment with BLU9931 and sorafenib. Data are expressed as a percentage of body weight at the initiation of treatment and are plotted as mean ± SEM.
Margit Hagel et al. Cancer Discovery 2015;5:
©2015 by American Association for Cancer Research